RESUMO

For a long time, dopaminergic treatment (DT) was the medication for restless legs syndrome. Although DT is effective and safe over the short-term, complications develop over longer periods, including augmentation, tolerance, and impulse control disorders. Nowadays, it is recommended that first-line treatment should be alpha-2 ligands, which are more effective in the absence of previous DT. As a second-line treatment, opioids, such as oxycodone extended-release with naloxone, are approved in Europe. Brain iron should be monitored before and during treatment and corrected if necessary. Two new promising non-DTs are being developed: perampanel and dipyridamole. More research is needed.

Assuntos

Síndrome das Pernas Inquietas/tratamento farmacológico , Analgésicos Opioides/uso terapêutico , Dopamina/efeitos adversos , Dopamina/uso terapêutico , Humanos , Ferro/análise , Ligantes , Ensaios Clínicos Controlados Aleatórios como Assunto , Resultado do Tratamento